ONCIN — Oncoinvent ASA Income Statement
0.000.00%
Last trade - 00:00- NOK147.40m
- NOK147.18m
- NOK8.10m
Annual income statement for Oncoinvent ASA, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | NAS | NAS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.4 | 11.1 | 6.28 | 5.79 | 8.1 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 70.6 | 91.9 | 117 | 153 | 149 |
| Operating Profit | -60.3 | -80.8 | -111 | -147 | -141 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -59.2 | -80.3 | -106 | -144 | -140 |
| Net Income After Taxes | -59.2 | -80.3 | -106 | -144 | -140 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -59.2 | -80.3 | -106 | -144 | -140 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -59.2 | -80.3 | -106 | -144 | -140 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.642 | -0.87 | -1.15 | -1.56 | -1.52 |